login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

FDA clears Trevo Pro Retrieval System to treat acute ischaemic stroke


Tuesday, 14 Aug 2012 10:04
Trevo Pro Retriever
Trevo Pro Retriever

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Stryker for its Trevo Pro Retriever, a clot removal technology designed to treat patients experiencing acute ischaemic stroke.  


The Trevo Pro Retriever demonstrated strong clinical results in the TREVO 2 clinical trial presented at the 2012 European Stroke Conference in May, in Lisbon. This technology demonstrated the highest rate of revascularisation in a randomised embolectomy stroke device trial, and achieved significantly better post-procedure revascularisation than the Merci Retriever (Concentric Medical/Stryker)―92% in the Trevo Retriever arm compared to 76.7% in the Merci Retriever arm.

Other measures of performance also strongly favored the TrevoPro Retriever, including improvement in the National Institutes of Health Stroke Scale (NIHSS) score, excellent composite safety endpoints and shorter hospital stays.


“The launch of this device is another great stride in the evolution of stroke care,” said Gary Duckwiler, TREVO 2 investigator, University of California Los Angeles Medical Center. “Concentric Medical, which is now owned by Stryker, has a long history of partnering with physicians to develop devices specifically designed to remove blood clots from a blocked artery in the brain. The new TrevoPro Retriever is easy to use and very effective at opening blood vessels; allowing physicians to have a significant impact on clinical outcomes.”


“In this patient population, rapidly restoring blood flow to the brain is critical,” said neurologist Wade Smith, University of California San Francisco Medical Center. “This technology advances our ability to help many patients avoid the devastating effects from a large stroke if they can get to a comprehensive stroke centre quickly for treatment.”




Add New Comment

Related Items


Most popular


MR CLEAN: expert opinion
Tuesday, 18 Nov 2014
Since the first presentation of data at the World Stroke Congress, the MR CLEAN trial has sent a ripple across the entire neurointerventional arena, raising questions about the future of stroke ... MR CLEAN: expert opinion

First patient treated in US pivotal trial evaluating cerebral protection during TAVI
Thursday, 09 Oct 2014
The randomised controlled SENTINEL Trial is the first in the USA to study capture and removal of debris released during TAVI that may otherwise be the source of stroke. First patient treated in US pivotal trial evaluating cerebral protection during TAVI

New Envoy catheters launched
Saturday, 11 Oct 2014
Codman Neuro has announced the Europe, Middle East and Africa launch of the Envoy DA XB Distal Access Guiding Catheter and the 7F Envoy Guiding Catheter for neurovascular procedures. New Envoy catheters launched

Features


The changing face of traumatic brain injury: Life beyond the guidelines
Tuesday, 18 Nov 2014
András Büki and Andrew Maas write that despite considerable efforts both in basic and clinical research, there has not been a major breakthrough in the care of the head injured in the last three ... The changing face of traumatic brain injury: Life beyond the guidelines

Neuro-oncologic treatment for glioblastoma
Monday, 21 Jul 2014
Malignant gliomas are the most common type of primary malignant brain tumour, accounting for 80% of patients and an annual incidence of 5.26 per 100,000 population, or 17,000 new cases diagnosed per ... Neuro-oncologic treatment for glioblastoma

Profiles


Vladimír Beneš Jr
Tuesday, 30 Sep 2014
Vladimír Beneš Jr is professor and chair at the First Medical School, Charles University, P... Vladimír Beneš Jr

Mauricio Castillo
Monday, 14 Jul 2014
Mauricio Castillo is a professor of Radiology and chief, Division of Neuroradiology, University of N... Mauricio Castillo

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions